Malonyl-CoA-acyl carrier protein transacylase (MCAT) is a nuclear-encoded mitochondrial enzyme essential for the mitochondrial fatty acid synthesis (mtFAS II) pathway. As cancer cells and metabolic disorders show high dependency on mitochondrial lipid biogenesis, MCAT has emerged as a novel therapeutic target. Developing highly selective small molecules requires robust biochemical and cell-based screening tools.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MCAT drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MCAT Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli or HEK293 expressed. |
View MCAT Products |
| Gene Delivery | MCAT Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and mitochondrial localization assays. |
View MCAT Products |
| Benchmark Ab | Anti-MCAT Recombinant Antibody Recombinant positive control for western blot, IHC, and target engagement validation. |
View MCAT Products |
| Validator | MCAT siRNA Set For knockdown verification in target validation studies. |
View MCAT Products |
| Related Target A | FASN (Fatty Acid Synthase) Cytosolic fatty acid synthesis counterpart. Crucial for selectivity profiling. |
View FASN Products |
| Related Target B | ACSF3 (Acyl-CoA Synthetase) Upstream enzyme in the mtFAS pathway converting malonate to malonyl-CoA. |
View ACSF3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mitochondrial targeting sequence interference | Truncated and mature form MCAT recombinant proteins designed with theoretical MW verification for optimal in vitro assay stability. |
| Selectivity screening against cytosolic lipid pathways | High-purity FASN and ACSF3 proteins available for off-target counter-screening panels. |
| Lack of Controls | Sequence-verified benchmark antibodies included for target localization confirmation. |
| False Positives in Small Molecule Screen | Validated siRNA sets included for functional knockdown comparison. |
Live MCAT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MCAT therapeutics is intensifying, with major players shifting focus from traditional metabolic enzymes to mitochondrial fatty acid synthesis (mtFAS) pathway inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting highly selective small molecule inhibitors that can disrupt mitochondrial membrane potential and respiration in cancer cells without causing systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutions, Biotech Startups | Solid Tumors, Metabolic Syndrome | Enzymatic Activity Assay (Need high-purity, sequence-verified MCAT protein) |
| RNA Therapeutics | Preclinical Biotech Companies | NASH / MASH, Rare Metabolic Disorders | Target Knockdown Validation (Need validated siRNA and Lentivirus) |
| Gene Therapy | Academic Research Centers | MCAT Deficiency, Optic Neuropathy | Rescue and Expression Assays (Need high-titer Lentivirus ORF) |